Elevidys’ Restricted Label Helps Sarepta Pressure Payers For Coverage Of DMD Gene Therapy

 
• By Derrick Gingery
Sarepta website
The initial accelerated approval of Elevidys restricted use to four- and five-year-old ambulatory DMD patients. • Source: Shutterstock

More from Market Access

More from Pink Sheet